US3051621A
(en)
*
|
1959-10-22 |
1962-08-28 |
Grove Lab Inc |
Gel composition, pressurized container with same, and method of preparation
|
US3050443A
(en)
*
|
1960-02-16 |
1962-08-21 |
James F Schuyler |
Headache remedy containing ammonia
|
US3039928A
(en)
*
|
1960-03-17 |
1962-06-19 |
Abbott Lab |
Stable aqueous isoproteronol compositions
|
NL262354A
(en)
*
|
1960-03-17 |
|
|
|
US3088874A
(en)
*
|
1960-05-23 |
1963-05-07 |
Union Carbide Corp |
Powder aerosol
|
US3282781A
(en)
*
|
1960-11-25 |
1966-11-01 |
Merck & Co Inc |
Inhalant compositions
|
BE632504A
(en)
*
|
1962-05-24 |
|
|
|
US3169095A
(en)
*
|
1962-10-30 |
1965-02-09 |
Rexall Drug Chemical |
Self-propelling powder-dispensing compositions
|
NL302251A
(en)
*
|
1963-01-28 |
1965-10-11 |
|
|
US3710782A
(en)
*
|
1969-10-01 |
1973-01-16 |
Hauser Res And Eng Co |
Method of treating human skin with a composition for electromedical applications
|
IL51314A
(en)
*
|
1976-01-30 |
1980-03-31 |
Fisons Ltd |
Disodium cromoglycate of low moisture content and pharmaceutical compositions containing it
|
AU522792B2
(en)
*
|
1977-07-19 |
1982-06-24 |
Fisons Plc |
Pressure pack formulation
|
US4352789A
(en)
*
|
1980-03-17 |
1982-10-05 |
Minnesota Mining And Manufacturing Company |
Aerosol compositions containing finely divided solid materials
|
US4655231A
(en)
*
|
1984-01-09 |
1987-04-07 |
Advanced Tobacco Products, Inc. |
Snuff and preparation thereof
|
US4576949A
(en)
*
|
1984-05-07 |
1986-03-18 |
The Upjohn Company |
Use of 5,6,7,8-tetrahydroquinolines and 5,6-dihydropyrindines as leukotriene and lipoxygenase inhibitors and the novel 3-substituted compounds therein
|
EP0213108A3
(en)
*
|
1985-06-26 |
1987-07-15 |
Kurt Dr. Burghart |
Pharmaceutical preparation containing an antihypotonic as the active agent
|
JPH0645538B2
(en)
*
|
1987-09-30 |
1994-06-15 |
日本化薬株式会社 |
Nitroglycerin spray
|
FR2625677A1
(en)
*
|
1988-01-07 |
1989-07-13 |
Cosnier Alain |
Medicinal composition intended for administration in aerosol form
|
GB2216794B
(en)
*
|
1988-03-22 |
1991-11-20 |
Fisons Plc |
Pharmaceuticals compositions
|
US5225183A
(en)
*
|
1988-12-06 |
1993-07-06 |
Riker Laboratories, Inc. |
Medicinal aerosol formulations
|
US5766573A
(en)
|
1988-12-06 |
1998-06-16 |
Riker Laboratories, Inc. |
Medicinal aerosol formulations
|
US5439670A
(en)
*
|
1989-11-28 |
1995-08-08 |
Riker Laboratories, Inc. |
Medicinal aerosol formulations
|
DE4003270A1
(en)
*
|
1990-02-03 |
1991-08-08 |
Boehringer Ingelheim Kg |
NEW SPEED GASES AND THEIR USE IN MEDICINE PREPARATIONS
|
US5118494A
(en)
*
|
1990-03-23 |
1992-06-02 |
Minnesota Mining And Manufacturing Company |
Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
|
US5175152A
(en)
*
|
1990-09-28 |
1992-12-29 |
Singh Nikhilesh N |
Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
|
MX9203481A
(en)
*
|
1990-10-18 |
1992-07-01 |
Minnesota Mining & Mfg |
FORMULATIONS.
|
US5785952A
(en)
*
|
1990-11-09 |
1998-07-28 |
Glaxo Group Limited |
Aerosol medicament formulation having a surface coating of surfactant
|
US5919435A
(en)
|
1990-11-09 |
1999-07-06 |
Glaxo Group Limited |
Aerosol formulation containing a particulate medicament
|
DK1277467T3
(en)
|
1991-06-10 |
2007-01-15 |
Schering Corp |
Formulations of non-chlorofluorocarbon aerosols
|
US5234933A
(en)
*
|
1991-10-31 |
1993-08-10 |
Board Of Governors Of Wayne State University And Vanderbilt University |
Cyclic hydroxamic acids
|
US5653962A
(en)
*
|
1991-12-12 |
1997-08-05 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicaments
|
IL104068A
(en)
*
|
1991-12-12 |
1998-10-30 |
Glaxo Group Ltd |
Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
|
CA2421976C
(en)
*
|
1991-12-12 |
2004-04-20 |
Glaxo Group Limited |
Medicaments
|
US5744123A
(en)
*
|
1991-12-12 |
1998-04-28 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicaments
|
US5736124A
(en)
*
|
1991-12-12 |
1998-04-07 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicament
|
US5658549A
(en)
*
|
1991-12-12 |
1997-08-19 |
Glaxo Group Limited |
Aerosol formulations containing propellant 134a and fluticasone propionate
|
ES2079210T3
(en)
*
|
1991-12-12 |
1996-01-01 |
Glaxo Group Ltd |
PHARMACEUTICAL FORMULATION OF AEROSOL.
|
US5674471A
(en)
*
|
1991-12-12 |
1997-10-07 |
Glaxo Group Limited |
Aerosol formulations containing P134a and salbutamol
|
US5916540A
(en)
*
|
1994-10-24 |
1999-06-29 |
Glaxo Group Limited |
Aerosol formulations containing P134A and/or P227 and particulate medicament
|
US7105152B1
(en)
|
1991-12-18 |
2006-09-12 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
US7101534B1
(en)
|
1991-12-18 |
2006-09-05 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
ATE260641T1
(en)
*
|
1991-12-18 |
2004-03-15 |
Minnesota Mining & Mfg |
AEROSOL COMPOSITIONS FOR MEDICINAL SUSPENSIONS
|
SK280911B6
(en)
*
|
1992-12-09 |
2000-09-12 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Pharmaceutical composition
|
DK0632008T3
(en)
*
|
1993-06-01 |
1998-09-23 |
Ono Pharmaceutical Co |
Penta Acid Derivatives
|
EP0640609A1
(en)
*
|
1993-08-24 |
1995-03-01 |
Ono Pharmaceutical Co., Ltd. |
Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species
|
ATE164834T1
(en)
*
|
1993-12-03 |
1998-04-15 |
Ono Pharmaceutical Co |
AMIDINOPHENOL DERIVATIVES WITH PHOSPHOLIPASE A2 INHIBITORY EFFECT
|
AU680967B2
(en)
*
|
1993-12-20 |
1997-08-14 |
Minnesota Mining And Manufacturing Company |
Flunisolide aerosol formulations
|
KR100226619B1
(en)
|
1994-09-20 |
1999-10-15 |
우에노 토시오 |
Amidinophenol derivative as protease inhibitors
|
US5840213A
(en)
*
|
1995-04-28 |
1998-11-24 |
Great Lakes Chemical Corporation |
Uses of heptafluoropropane
|
US5679287A
(en)
*
|
1995-04-28 |
1997-10-21 |
Great Lakes Chemical Corporation |
Uses of heptafluoropropane
|
KR980009238A
(en)
|
1995-07-28 |
1998-04-30 |
우에노 도시오 |
Sulfonyl amino acid derivative
|
EP0757984B1
(en)
*
|
1995-08-08 |
2002-10-30 |
Ono Pharmaceutical Co., Ltd. |
Hydroxamic acid derivatives useful for inhibiting gelatinase
|
AUPN814496A0
(en)
*
|
1996-02-19 |
1996-03-14 |
Monash University |
Dermal penetration enhancer
|
US5861268A
(en)
*
|
1996-05-23 |
1999-01-19 |
Biomide Investment Limited Partnership |
Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase
|
US6054488A
(en)
*
|
1996-06-11 |
2000-04-25 |
3M Innovative Properties Company |
Medicinal aerosol formulations of formoterol
|
GB9616237D0
(en)
*
|
1996-08-01 |
1996-09-11 |
Norton Healthcare Ltd |
Aerosol formulations
|
US6461591B1
(en)
|
1997-02-05 |
2002-10-08 |
Jago Research Ag |
Medical aerosol formulations
|
US5891419A
(en)
*
|
1997-04-21 |
1999-04-06 |
Aeropharm Technology Limited |
Environmentally safe flunisolide aerosol formulations for oral inhalation
|
US6129905A
(en)
*
|
1997-04-21 |
2000-10-10 |
Aeropharm Technology, Inc. |
Aerosol formulations containing a sugar as a dispersant
|
US5891420A
(en)
*
|
1997-04-21 |
1999-04-06 |
Aeropharm Technology Limited |
Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
|
US7153866B1
(en)
*
|
1997-05-27 |
2006-12-26 |
The United States Of America As Represented By The Department Of Health And Human Services |
Use of tempol for the treatment of Li-Fraumeni syndrome and ataxia telangiectasia
|
US20010031244A1
(en)
*
|
1997-06-13 |
2001-10-18 |
Chiesi Farmaceutici S.P.A. |
Pharmaceutical aerosol composition
|
JPH11187882A
(en)
|
1997-12-26 |
1999-07-13 |
Ono Pharmaceut Co Ltd |
Novel polypeptide, its production, cdna coding for the same polypeptide, vector comprising the same cdna, host cell transformed by the same vector, antibody of the same polypeptide, and pharmaceutical composition containing the polypeptide of antibody
|
JP4570251B2
(en)
|
1998-07-24 |
2010-10-27 |
ヤゴテック アーゲー |
Pharmaceutical aerosol formulation
|
US6475467B1
(en)
|
1998-08-04 |
2002-11-05 |
Jago Research Ag |
Medicinal aerosol formulations
|
US6136294C1
(en)
*
|
1998-09-22 |
2002-09-24 |
Aeropharm Technology Inc |
Amino acid stabilized medical aerosol formulation
|
US6458338B1
(en)
|
1998-09-22 |
2002-10-01 |
Aeropharm Technology Incorporated |
Amino acid stabilized medicinal aerosol formulations
|
DZ2947A1
(en)
*
|
1998-11-25 |
2004-03-15 |
Chiesi Farma Spa |
Pressure metered dose inhaler.
|
US6315985B1
(en)
*
|
1999-06-18 |
2001-11-13 |
3M Innovative Properties Company |
C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
EP1417975B1
(en)
|
2001-07-23 |
2011-03-02 |
Ono Pharmaceutical Co., Ltd. |
Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
|
EP2281818A1
(en)
|
2002-02-19 |
2011-02-09 |
Ono Pharmaceutical Co., Ltd. |
Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
|
US7582284B2
(en)
*
|
2002-04-17 |
2009-09-01 |
Nektar Therapeutics |
Particulate materials
|
US20050181032A1
(en)
*
|
2002-06-25 |
2005-08-18 |
Acrux Dds Pty Ltd. |
Metastable pharmaceutical compositions
|
US20050186141A1
(en)
*
|
2002-06-25 |
2005-08-25 |
Acrux Dds Pty Ltd. |
Transdermal aerosol compositions
|
EA009024B1
(en)
*
|
2002-06-25 |
2007-10-26 |
АКРУКС ДиДиЭс ПиТиУай ЭлТиДи |
Pharmaceutical composition for transdermal delivery of an active agent (variants)
|
EP2508204B1
(en)
|
2002-06-26 |
2014-09-24 |
Ono Pharmaceutical Co., Ltd. |
Remedies for diseases caused by vascular contraction or dilation
|
PT1537878E
(en)
|
2002-07-03 |
2010-11-18 |
Ono Pharmaceutical Co |
Immunopotentiating compositions
|
TW200408393A
(en)
|
2002-10-03 |
2004-06-01 |
Ono Pharmaceutical Co |
Antagonist of lysophosphatidine acid receptor
|
EP1563845A4
(en)
*
|
2002-10-10 |
2008-02-20 |
Univ Kyoto |
REMEDIES FOR ALLERGIC DISEASES
|
PT1563846E
(en)
|
2002-10-10 |
2012-11-13 |
Ono Pharmaceutical Co |
Endogenous repair factor production promoters
|
EP2270051B1
(en)
|
2003-01-23 |
2019-05-15 |
Ono Pharmaceutical Co., Ltd. |
Antibody specific for human PD-1 and CD3
|
CN101928284A
(en)
|
2003-03-14 |
2010-12-29 |
小野药品工业株式会社 |
Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
|
EP1619193A4
(en)
|
2003-04-18 |
2010-08-11 |
Ono Pharmaceutical Co |
Spiropiperidine compound and medicinal use thereof
|
CA2526222A1
(en)
*
|
2003-05-16 |
2004-12-02 |
Arriva Pharmaceuticals, Inc. |
Treatment of respiratory disease associated with matrix metalloprotease inhibitors
|
WO2006031210A1
(en)
*
|
2003-05-29 |
2006-03-23 |
Board Of Regents, The University Of Texas Systems |
Jabi as a prognostic marker and a therapeutic target for human cancer
|
US20070270489A1
(en)
|
2003-07-25 |
2007-11-22 |
Ono Pharmaceutical Co., Ltd. |
Remedy for Cartilage-Related Diseases
|
WO2005020882A2
(en)
|
2003-08-29 |
2005-03-10 |
Ono Pharmaceutical Co |
Compound capable of binding s1p receptor and pharmaceutical use thereof
|
NZ545666A
(en)
|
2003-09-01 |
2009-11-27 |
Ono Pharmaceutical Co |
Condensed ring compound and use thereof
|
WO2005025506A2
(en)
*
|
2003-09-10 |
2005-03-24 |
Map Pharmaceuticals, Inc. |
Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
|
KR20060106823A
(en)
*
|
2003-10-20 |
2006-10-12 |
쉐링 코포레이션 |
Pharmaceutical aerosol compositions
|
EP1698375B1
(en)
|
2003-12-25 |
2014-04-02 |
Ono Pharmaceutical Co., Ltd. |
Azetidine ring compounds and drugs comprising the same
|
WO2006004646A1
(en)
*
|
2004-06-28 |
2006-01-12 |
Nektar Therapeutics |
Aerosol formulation comprising nicotine salt
|
EP1806147B1
(en)
|
2004-10-21 |
2014-04-30 |
Ono Pharmaceutical Co., Ltd. |
Use of immunesuppressant receptor
|
ZA200704139B
(en)
*
|
2004-11-24 |
2008-10-29 |
Alcon Inc |
Method of delivering nasal spray
|
US8563581B2
(en)
|
2005-02-02 |
2013-10-22 |
Mitos Pharmaceuticals, Inc. |
Nitroxides for use in treating predisposed or at risk patients
|
US8524735B2
(en)
|
2005-05-18 |
2013-09-03 |
Mpex Pharmaceuticals, Inc. |
Aerosolized fluoroquinolones and uses thereof
|
CA2900093C
(en)
|
2005-05-18 |
2018-11-13 |
Mpex Pharmaceuticals, Inc. |
Aerosolized fluoroquinolones and uses thereof
|
US8114914B2
(en)
|
2005-06-17 |
2012-02-14 |
Wisconsin Alumni Research Foundation |
Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
|
JP5251127B2
(en)
|
2005-10-28 |
2013-07-31 |
小野薬品工業株式会社 |
COMPOUND CONTAINING BASIC GROUP AND USE THEREOF
|
EP1961745A1
(en)
|
2005-12-12 |
2008-08-27 |
Ono Pharmaceutical Co., Ltd. |
Bicyclic heterocyclic compound
|
JPWO2007069671A1
(en)
|
2005-12-15 |
2009-05-21 |
小野薬品工業株式会社 |
Bicyclic heterocyclic compounds
|
US20070286814A1
(en)
*
|
2006-06-12 |
2007-12-13 |
Medispray Laboratories Pvt. Ltd. |
Stable aerosol pharmaceutical formulations
|
EP2120875B1
(en)
|
2007-02-11 |
2018-07-11 |
Map Pharmaceuticals Inc. |
Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
|
TW200902019A
(en)
|
2007-04-26 |
2009-01-16 |
Ono Pharmaceutical Co |
Dicyclic heterocyclic compound
|
DE102008007198A1
(en)
|
2008-02-01 |
2009-08-13 |
Infectopharm Arzneimittel Und Consilium Gmbh |
Oral or nasally administrable formulations containing epinephrine with improved properties
|
PT2346509T
(en)
|
2008-10-07 |
2020-08-05 |
Horizon Orphan Llc |
Inhalation of levofloxacin for reducing lung inflammation
|
NZ631469A
(en)
|
2008-10-07 |
2016-06-24 |
Raptor Pharmaceuticals Inc |
Aerosol fluoroquinolone formulations for improved pharmacokinetics
|
TWI469965B
(en)
|
2008-12-22 |
2015-01-21 |
Ono Pharmaceutical Co |
Ethynylindole compounds
|
JP5621771B2
(en)
|
2009-06-17 |
2014-11-12 |
小野薬品工業株式会社 |
New imidazopyridine compounds
|
US20110171141A1
(en)
*
|
2009-06-26 |
2011-07-14 |
Kellerman Donald J |
Administration of dihydroergotamine mesylate particles using a metered dose inhaler
|
BR112012004692B8
(en)
|
2009-09-04 |
2021-05-25 |
Mpex Pharmaceuticals Inc |
solution comprising levofloxacin for use in a method of treating cystic fibrosis in a human.
|
WO2011066537A1
(en)
|
2009-11-30 |
2011-06-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Nitroxide therapy for the treatment of von hippel - lindau disease (vhl) and renal clear cell carcinoma (rcc)
|
AU2011270297B2
(en)
|
2010-06-21 |
2014-07-03 |
Ono Pharmaceutical Co., Ltd. |
Novel crystalline forms of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy] phenyl}ethynyl)-2-methyl-1h-indole-1,3-diyl]dibutanoic acid,4,4'- [2-methyl-7-({4-[4-(pentafluorophenyl) butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutanoic acid, and 4,4'-[4-fluoro-2-methyl-7- ({4-[4-(2,3,4,6-tetrafluorophenyl) butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutanoic acid
|
CA2818161A1
(en)
|
2010-12-02 |
2012-06-07 |
Ono Pharmaceutical Co., Ltd. |
Novel compound and medical use thereof
|
HUE058753T2
(en)
|
2011-01-31 |
2022-09-28 |
Avalyn Pharma Inc |
Aerosol pirfenidone and pyridone analog compounds and uses thereof
|
WO2012127885A1
(en)
|
2011-03-18 |
2012-09-27 |
小野薬品工業株式会社 |
Tetrahydrocarboline derivative
|
US9242977B2
(en)
|
2012-04-26 |
2016-01-26 |
Ono Pharmaceutical Co., Ltd. |
Trk-inhibiting compound
|
BR122017003181A2
(en)
|
2013-02-19 |
2019-09-10 |
Ono Pharmaceutical Co |
trk inhibitor compound, pharmaceutical composition and medicament comprising said compound and its use for prophylaxis and / or therapy of trk related disease and / or for inhibiting trk
|
WO2015017728A1
(en)
|
2013-07-31 |
2015-02-05 |
Windward Pharma, Inc. |
Aerosol tyrosine kinase inhibitor compounds and uses thereof
|
NZ722927A
(en)
|
2014-01-10 |
2022-07-29 |
Avalyn Pharma Inc |
Aerosol pirfenidone and pyridone analog compounds and uses thereof
|
EP3099672A4
(en)
|
2014-01-31 |
2017-09-20 |
ONO Pharmaceutical Co., Ltd. |
Fused imidazole compounds
|
EP3549957A4
(en)
|
2016-11-30 |
2020-08-05 |
Sumitomo Dainippon Pharma Co., Ltd. |
Wt1 helper peptide, and combination of said peptide and cancer antigen peptide conjugate
|
WO2018181648A1
(en)
|
2017-03-30 |
2018-10-04 |
大日本住友製薬株式会社 |
Wt1 cancer antigen peptide and peptide conjugate body containing same
|
JPWO2019049891A1
(en)
|
2017-09-06 |
2020-10-15 |
小野薬品工業株式会社 |
Cancer treatment method by combined use of Trk inhibitor and kinase inhibitor
|
US12240903B2
(en)
|
2018-05-31 |
2025-03-04 |
Ono Pharmaceutical Co., Ltd. |
Biomarkers for determining the effectiveness of immune checkpoint inhibitors
|
TWI855000B
(en)
|
2018-10-11 |
2024-09-11 |
日商小野藥品工業股份有限公司 |
Sting agonist compound
|
BR112022002098A2
(en)
|
2019-08-05 |
2022-04-12 |
Nat Cancer Ct |
Biomarkers to determine the effectiveness of immune signaling pathway inhibitors
|
US20230014137A1
(en)
|
2019-11-29 |
2023-01-19 |
Ono Pharmaceutical Co., Ltd. |
Compound having lysophosphatidic acid receptor agonist activity and pharmaceutical use thereof
|
US20230151024A1
(en)
|
2020-04-10 |
2023-05-18 |
Ono Pharmaceutical Co., Ltd. |
Sting agonistic compound
|
EP4151227A4
(en)
|
2020-05-12 |
2025-01-15 |
Sumitomo Pharma Co Ltd |
PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER
|
WO2022240897A1
(en)
|
2021-05-10 |
2022-11-17 |
Sepelo Therapeutics, Llc |
Pharmaceutical composition comprising delafloxacin for administration into the lung
|
WO2022251679A1
(en)
|
2021-05-27 |
2022-12-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Nitroxide radicals for use as antiviral treatment for coronavirus infection
|
WO2023028364A1
(en)
|
2021-08-27 |
2023-03-02 |
Sepelo Therapeutics, Llc |
Targeted compositions and uses therof
|